Impact of HLA-B*35 subtype differences on HIV disease outcome in Mexico.
HLA-B35 has consistently been associated with rapid HIV disease progression, particularly alleles of the Px group. As B35 is the most prevalent HLA-B in Mexico, we investigated HIV disease outcome in relation to HLA expression in a large cohort (n=976) of Mexicans. Contrary to the previous studies, no impact on viral load or CD4 cell count was observed in association with the B35 PY/Px groups. However, we observed differences in HIV disease outcome associated with specific HLA-B35 alleles.
aDepartment of Paediatrics, University of Oxford, Oxford, UK bCentre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico. *Claudia I. Juarez-Molina and Humberto Valenzuela-Ponce contributed equally to the writing of this article.
Claudia I
CI
Juarez-Molina
Humberto
H
Valenzuela-Ponce
Santiago
S
Avila-Rios
Daniela
D
Garrido-Rodriguez
Thalía
T
Garcia-Tellez
Maribel
M
Soto-Nava
Claudia
C
Garcia-Morales
Philip
P
Goulder
Gustavo
G
Reyes-Teran
D000483:Alleles; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D015658:HIV Infections / Q000235:genetics / Q000276:immunology* / Q000821:virology*; D015797:HLA-B35 Antigen / Q000235:genetics*; D006801:Humans; D008800:Mexico; D016896:Treatment Outcome; D019562:Viral Load
D015797:HLA-B35 Antigen